Anti-Allergy & Anti-Inflammatory Drops

Olopatadine Hydrochloride (0.1%, 0.2% w/v) is a dual-action mast cell stabilizer and selective histamine H1 receptor antagonist on the WHO Model List of Essential Medicines. It blocks H1 receptors on conjunctival nerves and vascular endothelium (providing rapid relief of itching within 30 minutes) and stabilizes mast cell membranes, inhibiting histamine, tryptase, and leukotriene degranulation. Indicated for the treatment of signs and symptoms of allergic conjunctivitis (seasonal and perennial).

Bromfenac Sodium (0.09% w/v eye drops) is a potent brominated ophthalmic NSAID. Bromination confers high lipophilicity, allowing rapid corneal penetration and prolonged inhibition of cyclooxygenase-2 (COX-2) in iris, ciliary body, and retina, providing sustained 24-hour relief of ocular pain and inflammation with once- or twice-daily dosing. Indicated for post-operative ocular inflammation and pain following cataract surgery.

Nepafenac (0.1% w/v eye drops) is an ophthalmic non-steroidal anti-inflammatory prodrug. It penetrates the cornea rapidly, where intraocular hydrolases convert it into amfenac, a potent cyclooxygenase (COX-1 and COX-2) inhibitor, suppressing prostaglandin synthesis in the anterior and posterior chambers. Indicated for the prevention and treatment of post-operative ocular pain and inflammation, and reduction in the risk of macular edema associated with cataract surgery in diabetic patients.

Moxifloxacin and NSAID (Bromfenac 0.09% or Ketorolac 0.5%) ophthalmic solution is an antibacterial and non-steroidal anti-inflammatory combination. Moxifloxacin provides broad bactericidal coverage, while the ophthalmic NSAID inhibits cyclooxygenase (COX-1/COX-2) enzymes to block prostaglandin synthesis, relieving ocular pain, photophobia, and anterior chamber flare without the intraocular pressure spikes or cataract risks associated with steroids. Indicated for post-cataract surgery ocular pain, inflammation, and infection prophylaxis.

Prednisolone Acetate / Sodium Phosphate (1% w/v eye drops) is the gold-standard topical ophthalmic corticosteroid on the WHO Model List of Essential Medicines. It delivers high corneal and intraocular penetration, suppressing cellular infiltration, capillary dilatation, fibroblast proliferation, and collagen deposition in the anterior segment. Indicated for steroid-responsive ocular inflammation (anterior uveitis, post-operative cataract inflammation, severe allergic blepharoconjunctivitis, and corneal graft rejection prophylaxis).

Prednisolone Acetate / Sodium Phosphate (1% w/v eye drops) is the gold-standard topical ophthalmic corticosteroid on the WHO Model List of Essential Medicines. It delivers high corneal and intraocular penetration, suppressing cellular infiltration, capillary dilatation, fibroblast proliferation, and collagen deposition in the anterior segment. Indicated for steroid-responsive ocular inflammation (anterior uveitis, post-operative cataract inflammation, severe allergic blepharoconjunctivitis, and corneal graft rejection prophylaxis).

Moxifloxacin and Corticosteroid (Dexamethasone 0.1% or Prednisolone 1%) ophthalmic drops is a broad-spectrum anti-infective and potent anti-inflammatory combination. Moxifloxacin (0.5%), a 4th-generation fluoroquinolone, inhibits bacterial DNA gyrase and topoisomerase IV across Gram-positive, Gram-negative, and atypical pathogens, while the steroid suppresses ocular surgical trauma, anterior chamber inflammation, and corneal edema. Indicated for post-operative prevention and treatment of inflammation and infection following cataract, refractive, or vitreoretinal surgery.

Flurbiprofen 0.03% w/v Eye Drop 5ml is an evidence-based ophthalmic/otic formulation. It acts by delivering targeted active therapeutic substances to external ocular or auditory tissues to control infection, relieve inflammation, or restore tissue homeostasis.

Fluorometholone (0.1% w/v ophthalmic suspension) is a surface-active fluorinated synthetic topical corticosteroid. It undergoes rapid enzymatic metabolism in the anterior chamber, conferring robust anti-inflammatory relief of conjunctival and superficial corneal inflammation while possessing significantly lower propensity to elevate intraocular pressure than dexamethasone or prednisolone. Indicated for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment.

Moxifloxacin and NSAID (Bromfenac 0.09% or Ketorolac 0.5%) ophthalmic solution is an antibacterial and non-steroidal anti-inflammatory combination. Moxifloxacin provides broad bactericidal coverage, while the ophthalmic NSAID inhibits cyclooxygenase (COX-1/COX-2) enzymes to block prostaglandin synthesis, relieving ocular pain, photophobia, and anterior chamber flare without the intraocular pressure spikes or cataract risks associated with steroids. Indicated for post-cataract surgery ocular pain, inflammation, and infection prophylaxis.

Olopatadine Hydrochloride (0.1%, 0.2% w/v) is a dual-action mast cell stabilizer and selective histamine H1 receptor antagonist on the WHO Model List of Essential Medicines. It blocks H1 receptors on conjunctival nerves and vascular endothelium (providing rapid relief of itching within 30 minutes) and stabilizes mast cell membranes, inhibiting histamine, tryptase, and leukotriene degranulation. Indicated for the treatment of signs and symptoms of allergic conjunctivitis (seasonal and perennial).